Infections In Hospitalized Patients With Psoriasis In A Skin Referral Hospital

Nafiseh Zaredar; Hamidreza  Mahmoudi; Tahereh Soori; Amir Teimourpour; Kamran Balighi; Ali Salehi Farid; Maryam Daneshpazhooh

doi:10.5826/dpc.1301a27

Infections In Hospitalized Patients With Psoriasis In A Skin Referral Hospital

Authors

Nafiseh Zaredar Department of Dermatology, Tehran University of Medical Sciences, Tehran, Iran.
Hamidreza Mahmoudi Autoimmune Bullous Diseases Research Center, Tehran University of Medical Sciences, Tehran, Iran.
Tahereh Soori Department of Dermatology, Tehran University of Medical Sciences, Tehran, Iran.
Amir Teimourpour Department of Dermatology, Tehran University of Medical Sciences, Tehran, Iran.
Kamran Balighi Department of Dermatology, Tehran University of Medical Sciences, Tehran, Iran.
Ali Salehi Farid Autoimmune Bullous Diseases Research Center, Tehran University of Medical Sciences, Tehran, Iran
Maryam Daneshpazhooh Autoimmune Bullous Diseases Research Center, Tehran University of Medical Sciences, Tehran, Iran

Keywords:

psoriasis, infection, biologic treatment, anti-TNFa, methotrexate

Abstract

Introduction: Psoriasis and its treatments may predispose patients to various infections. This is considered one of the most significant complications in patients with psoriasis.

Objectives: In the present study, we aimed to determine the prevalence of infection in hospitalized psoriasis patients and its relationship with systemic and biologic treatments.

Methods: All hospitalized patients with psoriasis from 2018 to 2020 in Razi Hospital in Tehran, Iran, were studied and cases of infection were recorded.

Results: Overall, 516 patients were studied and 25 types of infection in 111 patients were found. The most common types of infection were pharyngitis and cellulitis, followed by oral candida, urinary tract infections, common cold, fever of unknown origin, and pneumonia. Female sex and pustular psoriasis were significantly associated with infection in psoriatic patients. Those patients who received prednisolone had a higher risk of infection, and those under treatment with methotrexate or infliximab had a lower risk of infection.

Conclusion: Overall, 21.5% of psoriasis patients in our study had at least one episode of infection. This demonstrates that the prevalence of infection in these patients is not low. Using systemic steroids was associated with a higher risk of infection, while using methotrexate or infliximab was concomitant with a lower risk of infection.

References

Al Salman M, Ghiasi M, Farid AS, Taraz M, Azizpour A, Mahmoudi H. Oral simvastatin combined with narrowband UVB for the treatment of psoriasis: A randomized controlled trial. Dermatol Ther. 2021;34(5):e15075.

Parisi R, Iskandar IYK, Kontopantelis E, Augustin M, Griffiths CEM, Ashcroft DM. National, regional, and worldwide epidemiology of psoriasis: systematic analysis and modelling study. Bmj. 2020;369:m1590.

Lesan S, Toosi R, Aliakbarzadeh R, Daneshpazhooh M, Mahmoudi L, Tavakolpour S, et al. Oral Candida colonization and plaque type psoriasis: Is there any relationship? J Investig Clin Dent. 2018;9(3):e12335.

Pietrzak A, Grywalska E, Socha M, Rolinski J, Franciszkiewicz-Pietrzak K, Rudnicka L, et al. Prevalence and Possible Role of Candida Species in Patients with Psoriasis: A Systematic Review and Meta-Analysis. Mediators of inflammation. 2018;2018:9602362.

Yiu ZZ, Smith CH, Ashcroft DM, Lunt M, Walton S, Murphy R, et al. Risk of serious infection in patients with psoriasis receiving biologic therapies: a prospective cohort study from the British Association of Dermatologists Biologic Interventions Register (BADBIR). 2018;138(3):534-41.

Takeshita J, Shin DB, Ogdie A, Gelfand JM. Risk of Serious Infection, Opportunistic Infection, and Herpes Zoster among Patients with Psoriasis in the United Kingdom. The Journal of investigative dermatology. 2018;138(8):1726-35.

Wakkee M, de Vries E, van den Haak P, Nijsten TJJotAAoD. Increased risk of infectious disease requiring hospitalization among patients with psoriasis: a population-based cohort. 2011;65(6):1135-44.

Kalb RE, Fiorentino DF, Lebwohl MG, Toole J, Poulin Y, Cohen AD, et al. Risk of Serious Infection With Biologic and Systemic Treatment of Psoriasis: Results From the Psoriasis Longitudinal Assessment and Registry (PSOLAR). JAMA dermatology. 2015;151(9):961-9.

Kimball AB, Gladman D, Gelfand JM, Gordon K, Horn EJ, Korman NJ, et al. National Psoriasis Foundation clinical consensus on psoriasis comorbidities and recommendations for screening. 2008;58(6):1031-42.

Davila-Seijo P, Dauden E, Descalzo MA, Carretero G, Carrascosa JM, Vanaclocha F, et al. Infections in Moderate to Severe Psoriasis Patients Treated with Biological Drugs Compared to Classic Systemic Drugs: Findings from the BIOBADADERM Registry. The Journal of investigative dermatology. 2017;137(2):313-21.

Hsu DY GK, Silverberg JI. Serious infections in hospitalized patients with psoriasis in the United States. Journal of the American Academy of Dermatology. 2016;75(2):287-96.

Carneiro C, Bloom R, Ibler E, Majewski S, Sable KA, Guido NJ, et al. Rate of serious infection in patients who are prescribed systemic biologic or nonbiologic agents for psoriasis: A large, single center, retrospective, observational cohort study. 2017;30(5):e12529.

Yiu ZZ, Exton LS, Jabbar-Lopez Z, Mustapa MFM, Samarasekera EJ, Burden AD, et al. Risk of serious infections in patients with psoriasis on biologic therapies: a systematic review and meta-analysis. 2016;136(8):1584-91.

Garcia-Doval I, Cohen AD, Cazzaniga S, Feldhamer I, Addis A, Carretero G, et al. Risk of serious infections, cutaneous bacterial infections, and granulomatous infections in patients with psoriasis treated with anti–tumor necrosis factor agents versus classic therapies: Prospective meta-analysis of Psonet registries. 2017;76(2):299-308. e16.

Yiu ZZN, Ashcroft DM, Evans I, McElhone K, Lunt M, Smith CH, et al. Infliximab is associated with an increased risk of serious infection in patients with psoriasis in the U.K. and Republic of Ireland: results from the British Association of Dermatologists Biologic Interventions Register (BADBIR). The British journal of dermatology. 2019;180(2):329-37.

Dobry AS, Quesenberry CP, Ray GT, Geier JL, Asgari MM. Serious infections among a large cohort of subjects with systemically treated psoriasis. J Am Acad Dermatol. 2017;77(5):838-44.

Haddad A, Li S, Thavaneswaran A, Cook RJ, Chandran V, Gladman DD. The Incidence and Predictors of Infection in Psoriasis and Psoriatic Arthritis: Results from Longitudinal Observational Cohorts. The Journal of rheumatology. 2016;43(2):362-6.